Study on the mechanism of Cutaneous and Respiratory Comorbidities with Chinese and Western medicine theories and research

Abstract

In the realms of traditional Chinese medicine and Western medicine research, the skin and lungs are recognized for their integral roles in both the physiological functions and pathological mechanisms affecting the human body. These organs are not only complementary and coordinated in their physiological functions but also interact pathologically, providing feedback and influencing each other. The etiology of immune-mediated skin diseases is multifaceted, involving numerous factors beyond mere skin characteristics, often including multisystem diseases. Cutaneous and Respiratory Comorbidities denote the concurrent presence of skin and lung diseases, sharing a common pathogenic mechanism. Although research on Cutaneous and Respiratory Comorbidities has received increasing attention, the foundational theories and the specifics of related diseases remain unclear. This paper aims to elucidate the theoretical basis of both traditional Chinese and Western medicine concerning immune-mediated Cutaneous and Respiratory Comorbidities, thereby laying a groundwork for the early detection and integrated treatment of these diseases.

Keywords

Chinese medicine theory / comorbidities / immune diseases / lung / skin

References

[1] Dąbrowska AK, Spano F, Derler S, Adlhart C, Spencer N, Rossi R. The relationship between skin function, barrier properties, and body-dependent factors. Skin Res Technol. 2018; 24 (2): 165- 174.

[2] Cecilie S, Holloway JW, Krauss ES. Preconception origins of asthma, allergies and lung function: the influence of previous generations on the respiratory health of our children. J Intern Med. 2023; 293 (5): 531- 549.

[3] Wang XY, Li QZ. Research progress of lung relating to skin theory. SH.J.TCM Jan. 2006; 40: 1 (in Chinese).

[4] Kommoss KS, Enk A, Heikenwälder M, Waisman A, Karbach S, Wild J. Cardiovascular comorbidity in psoriasis -psoriatic inflammation is more than just skin deep. J Dtsch Dermatol Ges. 2023; 21 (7): 718- 725.

[5] Bruti G, Magnotti MC, Iannetti G. Migraine and depression: bidirectional co-morbidities? Neurol Sci. 2012; 33 (Suppl 1): S107- S109.

[6] Mosenzon O, Miller EM, Warren ML. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Postgrad Med. 2020; 132 (Suppl 2): 37- 47.

[7] Orlando G, Molon B, Viola A, Alaibac M, Angioni R, Piaserico S. Psoriasis and cardiovascular diseases: an immune-mediated cross talk? Front Immunol. 2022; 13: 868277.

[8] Zheng Y, Lv XD, Pang LJ, et al. A brief analysis on preventive treatment of disease thought based on theory of lung governing skin. Chinese Arch Trad Chinese Med. 2018; 09: 027 (in Chinese).

[9] Liu WH, Du H. Exploring the relationship between "lung governing skin" and the onset of atopic dermatitis from the ancient books of traditional Chinese medicine. Med J NDFN. 2017; 38: 11 (in Chinese).

[10] Bai YP, Zhang LY. The basis of the theory of " lung governing skin" was discussed from the perspective of the correlation between allergic skin diseases and lung diseases. J Beijing Univ Tradit Chin Med. 2008; 11 (6): 15 (in Chinese).

[11] Deckers J, De Bosscher K, Lambrecht BN, Hammad H. Interplay between barrier epithelial cells and dendritic cells in allergic sensitization through the lung and the skin. Immunol Rev. 2017; 278 (1): 131- 144.

[12] Teaw S, Hinchcliff M, Cheng M. A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis. Rheumatology. 2021; 60 (12): 5498- 5508.

[13] Simon D, Wardlaw A, Rothenberg ME. Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol. 2010; 126 (1): 3- 13. quiz 14-5.

[14] Shin JI, Lee KH, Park S, et al. Systemic lupus erythematosus and lung involvement: a comprehensive review. J Clin Med. 2022; 11 (22): 6714.

[15] Kudo K, Hamaguchi Y, Iyobe R, et al. A case of anti-SAE antibody-positive clinically amyopathic dermatomyositis complicated by advanced gastric cancer and interstitial lung disease. Eur J Dermatol. 2023; 33 (3): 323- 325.

[16] Bellocchi C, Ying J, Goldmuntz EA, et al. Large-scale characterization of systemic sclerosis serum protein profile: comparison to peripheral blood cell transcriptome and correlations with skin/lung fibrosis. Arthritis Rheumatol. 2021; 73 (4): 660- 670.

[17] BaŞ İN, AtaĞ E, Ergenekon AP, et al. An adolescent presented with hemoptysis: pulmonary artery aneurysm in pediatric Behçet's disease. Arch Rheumatol. 2020; 35 (2): 283- 286.

[18] Chen KJ, Liu Q, Yu LD, et al. Observation of bulbar conjunctival microcirculation in a model of wind chill lung(pig). Chinese J Trad Med Sci Technol. 1994; 1 (6) (in Chinese).

[19] Williams ML, Bhatia SK. Engineering the extracellular matrix for clinical applications: endoderm, mesoderm, and ectoderm. Biotechnol J. 2014; 9 (3): 337- 347.

[20] Renshaw SA, Loynes CA, Elworthy S, Ingham PW, Whyte MKB. Modeling inflammation in the zebrafish: how a fish can help us understand lung disease. Exp Lung Res. 2007; 33 (10): 549- 554.

[21] Leclère R, Straus C, Similowski T, Bodineau L, Fiamma MN. Persistent lung oscillator response to CO₂ after buccal oscillator inhibition in the adult frog. Respir Physiol Neurobiol. 2012; 183 (2): 166- 169.

[22] Kimura N. Fictive lung ventilation in the isolated brainstem preparation of the aquatic frog, Xenopus laevis. Adv Exp Med Biol. 2010; 669: 9- 12.

[23] Sherratt MJ, Hopkinson L, Naven M, et al. Circadian rhythms in skin and other elastic tissues. Matrix Biol. 2019; 84: 97- 110.

[24] Motamedi M, Ferrara G, Yacyshyn E, et al. Skin disorders and interstitial lung disease: Part I-Screening, diagnosis, and therapeutic principles. J Am Acad Dermatol. 2023; 88 (4): 751- 764.

[25] Kemter AM, Nagler CR. Influences on allergic mechanisms through gut, lung, and skin microbiome exposures. J Clin Invest. 2019; 129 (4): 1483- 1492.

[26] Gulec KZ, Uysal P. Beyond the skin: reduced lung function associated with atopic dermatitis in infants. J Allergy Clin Immunol Pract. 2023; 11 (9): 2839- 2847.

[27] Ubags ND, Trompette A, Pernot J, et al. Microbiome-induced antigen-presenting cell recruitment coordinates skin and lung allergic inflammation. J Allergy Clin Immunol. 2021; 147 (3): 1049- 1062.

[28] Gu CY, Yao X, Li W. Burden of disease; the current status of the diagnosis and management of atopic dermatitis in China. J Clin Med. 2023; 12 (16): 5370.

[29] Chiricozzi A, Maurelli M, Calabrese L, Peris K, Girolomoni G. Overview of atopic dermatitis in different ethnic groups. J Clin Med. 2023; 12 (7): 2701.

[30] Hatano Y, Elias PM. Outside-to-inside, "inside-to-outside," and "intrinsic" endogenous pathogenic mechanisms in atopic dermatitis: keratinocytes as the key functional cells involved in both permeability barrier dysfunction and immunological alterations. Front Immunol. 2023; 14: 1239251.

[31] Wollenberg A, Werfel T, Ring J, et al. Atopic dermatitis in children and adults-diagnosis and treatment. Dtsch Arztebl Int. 2023; 120: 224- 234.

[32] Toppila-Salmi S, Chanoine S, Karjalainen J, et al. Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age. Allergy. 2019; 74 (12): 2406- 2416.

[33] Skevaki C, Ngocho JS, Amour C, Schmid-Grendelmeier P, Mmbaga BT, Renz H. Epidemiology and management of asthma and atopic dermatitis in Sub-Saharan Africa. J Allergy Clin Immunol. 2021; 148 (6): 1378- 1386.

[34] Wan J, Mitra N, Hoffstad OJ, Gelfand JM, Yan AC, Margolis DJ. Variations in risk of asthma and seasonal allergies between early-and late-onset pediatric atopic dermatitis: a cohort study. J Am Acad Dermatol. 2017; 77 (4): 634- 640.

[35] Tran MM, Lefebvre DL, Dharma C, et al. Predicting the atopic march: results from the Canadian healthy infant longitudinal development study. J Allergy Clin Immunol. 2018; 141 (2): 601- 607.

[36] Lowe AJ, Leung DYM, Tang MLK, Su JC, Allen KJ. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018; 120 (2): 145- 151.

[37] Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014; 69 (1): 17- 27.

[38] Chalmers JR, Haines RH, Mitchell EJ, et al. Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. Trials. 2017; 18 (1): 343.

[39] Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014; 134 (4): 818- 823.

[40] Sackesen C, Sekerel BE, Orhan F, Kocabas CN, Tuncer A, Adalioglu G. The etiology of different forms of urticaria in childhood. Pediatr Dermatol. 2004; 21 (2): 102- 108.

[41] Ma LL, Yu TG, Zhuang YR, et al. The relationship between changes in lung function in urticaria patients and the "lung governing skin" in traditional Chinese medicine. J Zhejiang Coll Trad Chinese Med. 2000; 08 (4): 24 (in Chinese).

[42] Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130 (3): 607- 612.

[43] Protheroe C, Woodruff SA, de Petris G, et al. A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2009; 7: 749- 755.

[44] Nair P, Ochkur SI, Protheroe C, Simms E, Lee NA, Lee JJ. The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma. Allergy Asthma Clin Immunol. 2011; 7 (1): 4.

[45] Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009; 124 (6): 1319- 1325.

[46] Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994; 83 (10): 2759- 2779.

[47] Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin. 2007; 27 (3): 415- 441.

[48] Fauci AS, Harley JB, Roberts WC, et al. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982; 97 (1): 78.

[49] Dulohery MM, Patel RR, Schneider F, Ryu JH. Lung involvement in hypereosinophilic syndromes. Respir Med. 2011; 105 (1): 114- 121.

[50] Benito-Garcia E, Schur PH, Lahita R. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum. 2004; 51 (6): 1030- 1044.

[51] Tench CM, McCurdie I, White PD, et al. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology. 2000; 39 (11): 1249- 1254.

[52] Iaboni A, Ibanez D, Gladman DD, et al. Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. J Rheumatol. 2006; 33: 2453.

[53] Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology. 2009; 48 (5): 542- 545.

[54] Tselios K, Urowitz MB. Cardiovascular and pulmonary manifestations of systemic lupus erythematosus. Curr Rheumatol Rev. 2017; 13 (3): 206.

[55] Wan SA, Teh CL, Jobli AT. Lupus pneumonitis as the initial presentation of systemic lupus erythematosus: case series from a single institution. Lupus. 2016; 25 (13): 1485- 1490.

[56] Sharma S, Smith R, Al-Hameed F. Fibrothorax and severe lung restriction secondary to lupus pleuritis and its successful treatment by pleurectomy. Can Respir J. 2002; 9 (5): 335- 337.

[57] Keane MP, Lynch JP, III. . Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax. 2000; 55 (2): 159- 166.

[58] Nakano M, Hasegawa H, Takada T, et al. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology. 2002; 7 (1): 45- 49.

[59] Matthay RA, Schwarz MI, Petty TL, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltim). 1975; 54 (5): 397- 410.

[60] Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. J Thorac Imag. 1992; 7 (2): 1- 18.

[61] O'Rielly DD, Jani M, Rahman P, Elder JT. The genetics of psoriasis and psoriatic arthritis. J Rheumatol Suppl. 2019; 95: 46- 50.

[62] Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009; 41 (2): 199- 204.

[63] Garcia VE, Chang M, Brandon R, et al. Detailed genetic characterization of the interleukin-23 receptor in psoriasis. Genes Immun. 2008; 9 (6): 546- 555.

[64] Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010; 62 (6): 979- 987.

[65] Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire-based survey. Br J Dermatol. 2013; 169 (2): 314- 319.

[66] Garg A, Gladman D. Recognizing psoriatic arthritis in the dermatology clinic. J Am Acad Dermatol. 2010; 63 (5): 733- 748.

[67] Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen A. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol. 2008; 159 (4): 956- 960.

[68] Ungprasert P, Srivali N, Thongprayoon C. Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Dermatolog Treat. 2016; 27 (4): 316- 321.

[69] Wu M, Varga J. In perspective: murine models of scleroderma. Curr Rheumatol Rep. 2008; 10 (3): 173- 182.

[70] Schachna L, Wigley FM, Morris S, Gelber AC, Rosen A, Casciola-Rosen L. Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum. 2002; 46 (7): 1873- 1884.

[71] Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol. 2018; 32 (2): 223- 240.

[72] Wu W, Jordan S, Graf N, et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 2019; 78 (5): 648- 656.

[73] Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J. 2010; 35 (1): 112- 117.

[74] Chung WS, Lin CL, Sung FC, et al. Systemic sclerosis increases the risks of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Rheumatology. 2014; 53 (9): 1639- 1645.

[75] Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008; 134 (3): 601- 605.

[76] van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014; 370 (5): 433- 443.

[77] Xanthouli P, Jordan S, Milde N, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis. 2020; 79 (3): 370- 378.

[78] Steen V, Chou M, Shanmugam V, Mathias M, Kuru T, Morrissey R. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest. 2008; 134 (1): 146- 151.

[79] Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019; 53 (1): 1801913.

[80] Baig S, Paik JJ. Inflammatory muscle disease - an update. Best Pract Res Clin Rheumatol. 2020; 34 (1): 101484.

[81] Moneta GM, Pires Marafon D, Marasco E, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis Rheumatol. 2019; 71 (6): 1011- 1021.

[82] Callen JP. Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep. 2010; 12 (3): 192- 197.

[83] Dugan EM, Huber AM, Miller FW, Rider LG, Unk U. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J. 2009; 15 (2): 1.

[84] Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008; 59 (5): 677- 685.

[85] Ikeda S, Arita M, Misaki K, et al. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. SpringerPlus. 2015; 4 (1): 240.

[86] Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009; 60 (7): 2183- 2192.

[87] Mariette X, Criswell LA. Primary Sjögren's syndrome. N Engl J Med. 2018; 378 (10): 931- 939.

[88] Wang X, Bootsma H, Terpstra J, et al. Progenitor cell niche senescence reflects pathology of the parotid salivary gland in primary Sjögren's syndrome. Rheumatology. 2020; 59 (10): 3003- 3013.

[89] Vivino FB, Bunya VY, Massaro-Giordano G, et al. Sjogren's syndrome: an update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019; 203: 81- 121.

[90] Ramos-Casals M, Brito-Zerón P, Seror R, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology. 2015; 54 (12): 2230- 2238.

[91] Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjögren syndrome. Chest. 2006; 130 (5): 1489- 1495.

[92] Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005; 171 (6): 632- 638.

[93] Strimlan CV, Rosenow EC, III , Divertie MB, Harrison EG. Pulmonary manifestations of Sjögren's syndrome. Chest. 1976; 70 (3): 354- 361.

[94] Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open. 2013; 3 (11): e003569.

[95] Rothnie KJ, Connell O, Müllerová H, et al. Myocardial infarction and ischemic stroke after exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2018; 15 (8): 935- 946.

[96] Meteran H, Backer V, Kyvik KO, Skytthe A, Thomsen SF. Comorbidity between chronic obstructive pulmonary disease and type 2 diabetes: a nation-wide cohort twin study. Respir Med. 2015; 109 (8): 1026- 1030.

[97] Villaverde-García V, Cobo-Ibáñez T, Candelas-Rodríguez G, et al. The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: a systematic literature review. Semin Arthritis Rheum. 2017; 46 (5): 569- 583.

[98] Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361 (5): 496- 509.

[99] O'Brien ME, Chandra D, Wilson RC, et al. Loss of skin elasticity is associated with pulmonary emphysema, biomarkers of inflammation, and matrix metalloproteinase activity in smokers. Respir Res. 2019; 20 (1): 128.

[100] Szczegielniak J, Bogacz K, Łuniewski J, Krajczy M, Pilis W, Majorczyk E. Excessive facial wrinkling is associated with COPD occurrence-does COPD damage skin beauty and quality? Int J Environ Res Publ Health. 2023; 20 (3): 1991.

[101] Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020; 383 (10): 958- 968.

[102] Suliman YA, Dobrota R, Huscher D, et al. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol. 2015; 67 (12): 3256- 3261.

[103] Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002; 165 (12): 1581- 1586.

[104] Belloli EA, Beckford R, Hadley R, Flaherty KR. Idiopathic non-specific interstitial pneumonia. Respirology. 2016; 21 (2): 259- 268.

[105] King TE, Jr, Kim EJ, Kinder BW. Connective tissue diseases. In: Schwartz MI, KingJr TE, eds. Interstitial Lung Disease. 5th. People's Medical Publishing House - USA; 2011. 689.

[106] Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004; 44 (6): 585- 596.

[107] Lawrence EC. Systemic lupus erythematosus and the lung. In: Lahita RG, ed. Systemic Lupus Erythematosus. John Wiley and Sons; 1987.

[108] Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43 (12 Suppl S): 13S- 24S.

[109] Komforti M, Jewell J, Pavlis M. Multiple clustered dermatofibromas associated with pulmonary arterial hypertension. Am J Dermatopathol. 2016; 38 (3): e30- e32.

[110] Brunetti-Pierri N, Piccolo P, Morava E, et al. Cutis laxa and fatal pulmonary hypertension: a newly recognized syndrome? Clin Dysmorphol. 2011; 20 (2): 77- 81.

[111] Fernandez-Anton Martinez MC, Parra-Blanco V, Izquierdo JA, Suarez Fernan dez RM. Cutaneous metastases of internal tumors. Actas Dermosifilogr. 2013; 104 (10): 841- 853.

[112] Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin. 2009; 59 (2): 73- 98.

[113] Silva JA, Mesquita Kde C, Igreja AC, et al. Paraneoplastic cutaneous manifestations: concepts and updates. An Bras Dermatol. 2013; 88 (1): 9- 22.

[114] Krawczyk M, Mykała-Cieśla J, Kołodziej-Jaskuła A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn. 2009; 119 (3): 180- 183.

[115] Rongioletti F, Fausti V, Parodi A. Erythema gyratum repens is not an obligate paraneoplastic disease: a systematic review of the literature and personal experience. J Eur Acad Dermatol Venereol. 2014; 28 (1): 112- 115.

[116] Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med. 1976; 84 (1): 68- 76.

[117] Fujita J, Tokuda M, Bandoh S, et al. Primary lung cancer associated with polymyositis/dermatomyositis, with a review of the literature. Rheumatol Int. 2001; 20 (2): 81- 84.

[118] Venkataraman D, Soto-Ramírez N, Kurukulaaratchy RJ, et al. Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence. J Allergy Clin Immunol. 2014; 134 (4): 876- 882.

[119] Noti M, Kim BS, Siracusa MC, et al. Exposure to food allergens through inflamed skin promotes intestinal food allergy through the thymic stromal lymphopoietin-basophil axis. J Allergy Clin Immunol. 2014; 133 (5): 1390- 1399.

[120] Han H, Xu W, Headley MB, et al. Thymic stromal lymphopoietin (TSLP)-mediated dermal inflammation aggravates experimental asthma. Mucosal Immunol. 2012; 5 (3): 342- 351.

[121] Leyva-Castillo JM, Hener P, Jiang H, Li M. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J Invest Dermatol. 2013; 133 (1): 154- 163.

[122] Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019; 143 (1): 1- 11.

[123] Muraro A, Lemanske RF, Jr , Hellings PW, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2016; 137 (5): 1347- 1358.

[124] Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019; 143 (1): 155- 172.

[125] Guttman-Yassky E. Lebrikizumab, a high affinity IL-13 inhibitor, improves clinical manifestations in moderate-to-severe atopic dermatitis: primary results from a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study. In: Fall Clinical Dermatology Conference; 2019.

[126] Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018; 378 (26): 2486- 2496.

[127] Schwendinger-Schreck J, Wilson SR, Bautista DM. Interactions between keratinocytes and somatosensory neurons in itch. Handb Exp Pharmacol. 2015; 226: 177- 190.

[128] Ostrowski SM, Belkadi A, Loyd CM, Diaconu D, Ward NL. Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner. J Invest Dermatol. 2011; 131 (7): 1530- 1538.

[129] Riol-Blanco L, Ordovas-Montanes J, Mario P, et al. Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation. Nature. 2014; 510 (7503): 157- 161.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Advanced Chinese Medicine published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.